Functional microRNA-Targeting Drug Discovery by Graph-Based Deep Learning.
Arash Keshavarzi ArshadiMilad SalemHeather KarnerKristle GarciaAbolfazl ArabJiann Shiun YuanHani GoodarziPublished in: bioRxiv : the preprint server for biology (2023)
MicroRNAs are recognized as key drivers in many cancers, but targeting them with small molecules remains a challenge. We present RiboStrike, a deep learning framework that identifies small molecules against specific microRNAs. To demonstrate its capabilities, we applied it to microRNA-21 (miR-21), a known driver of breast cancer. To ensure the selected molecules only targeted miR-21 and not other microRNAs, we also performed a counter-screen against DICER, an enzyme involved in microRNA biogenesis. Additionally, we used auxiliary models to evaluate toxicity and select the best candidates. Using datasets from various sources, we screened a pool of nine million molecules and identified eight, three of which showed anti-miR-21 activity in both reporter assays and RNA sequencing experiments. One of these was also tested in mouse models of breast cancer, resulting in a significant reduction of lung metastases. These results demonstrate RiboStrike’s ability to effectively screen for microRNA-targeting compounds in cancer.
Keyphrases
- deep learning
- cell proliferation
- long non coding rna
- cancer therapy
- drug discovery
- long noncoding rna
- high throughput
- convolutional neural network
- mouse model
- machine learning
- single cell
- artificial intelligence
- crispr cas
- drug delivery
- squamous cell carcinoma
- genome wide
- gene expression
- young adults
- childhood cancer
- squamous cell
- neural network